Innovation Pharmaceuticals Inc (IPIX)

[CallMeCrazy]

Basilea immediately came to mind after reading 'Frenchbroad's' comment. IMO, we shouldn't press her for her sources because confidentiality is essential to keeping the info pipeline open.

I think if you follow the link to their website, you will find that Basilea would be an excellent fit for IPIX. Here's why:

Basilea is a revenue-generating, commercial-stage Swiss biopharmaceutical company. Our activities are focused in the areas of hospital antibiotics and hospital antifungals. Our portfolio comprises of two marketed anti-infective brands (Cresemba® and Zevtera®) and several preclinical anti-infective assets. We are building on our potential for sustainable growth and valuation generation, based on increasing revenues and selective investments into internal and external innovation. Basilea was founded in 2000 and is located in the life sciences hub of the Basel area. Basilea has about 150 employees. Since 2004, Basilea is listed on the SIX Swiss Stock Exchange with the ticker symbol BSLN.

https://www.basilea.com/who-we-are

Don't forget IPIX can license B indications in the bacterial area and fungal area and still have the lucrative virus area for themselves or to further partner.

Basilea and IPIX have one thing in common. They both moved away from oncology.